Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VLS-01 in Treatment Resistant Depression
NCT06524830Phase 2Completed
- Sponsor
- atai Life Sciences
- Start
- Dec 2024
- Primary completion
- Jul 2026
- Modality
- Small Molecules
- Countries
- 4
01
Overview
A Phase 2 trial of MIND003 in treatment-resistant depression (TRD), sponsored by atai Life Sciences. Started Dec 2024; status: completed.
02
Drugs
MIND003
03
Conditions
treatment-resistant depression (TRD)
Beyond the preview
Go deeper on NCT06524830.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06524830.